PCAS SA

ENXTPA:PCA Stock Report

Market Cap: €109.9m

PCAS Past Earnings Performance

Past criteria checks 2/6

PCAS's earnings have been declining at an average annual rate of -40.1%, while the Life Sciences industry saw earnings growing at 27.3% annually. Revenues have been growing at an average rate of 0.7% per year. PCAS's return on equity is 122.1%, and it has net margins of 3.8%.

Key information

-40.1%

Earnings growth rate

-40.2%

EPS growth rate

Life Sciences Industry Growth26.8%
Revenue growth rate0.7%
Return on equity122.1%
Net Margin3.8%
Last Earnings Update30 Jun 2023

Recent past performance updates

Statutory Earnings May Not Be The Best Way To Understand PCAS' (EPA:PCA) True Position

Sep 14
Statutory Earnings May Not Be The Best Way To Understand PCAS' (EPA:PCA) True Position

Recent updates

Statutory Earnings May Not Be The Best Way To Understand PCAS' (EPA:PCA) True Position

Sep 14
Statutory Earnings May Not Be The Best Way To Understand PCAS' (EPA:PCA) True Position

Is PCAS (EPA:PCA) A Risky Investment?

Dec 19
Is PCAS (EPA:PCA) A Risky Investment?

Is PCAS (EPA:PCA) Weighed On By Its Debt Load?

May 24
Is PCAS (EPA:PCA) Weighed On By Its Debt Load?

Did You Miss PCAS' (EPA:PCA) 48% Share Price Gain?

Mar 02
Did You Miss PCAS' (EPA:PCA) 48% Share Price Gain?

PCAS'(EPA:PCA) Share Price Is Down 48% Over The Past Three Years.

Nov 25
PCAS'(EPA:PCA) Share Price Is Down 48% Over The Past Three Years.

Revenue & Expenses Breakdown

How PCAS makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

ENXTPA:PCA Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2323091490
31 Mar 23228-201490
31 Dec 22226-491490
30 Sep 22208-581460
30 Jun 22191-671430
31 Mar 22189-541400
31 Dec 21187-401370
30 Sep 21191-271350
30 Jun 21195-141330
31 Mar 21195-151320
31 Dec 20194-151320
30 Sep 20199-131310
30 Jun 20204-111300
31 Mar 20202-121270
31 Dec 19201-141230
30 Sep 19205-91810
30 Jun 19209-61200
31 Mar 19208-31190
31 Dec 1820701190
30 Sep 18208-1590
30 Jun 1820801170
31 Mar 1821331150
31 Dec 1721861140
30 Sep 1721061100
30 Jun 1720261070
31 Mar 1719761050
31 Dec 1619271030
30 Sep 1619171010
30 Jun 161898980
31 Mar 161848950
31 Dec 151799920
30 Sep 151757890
30 Jun 151725870
31 Mar 151694860
31 Dec 141663840
30 Sep 141642840
30 Jun 141612830
31 Mar 141633840
31 Dec 131653840
30 Jun 131716840
31 Mar 131716840
31 Dec 121716850

Quality Earnings: PCA has a high level of non-cash earnings.

Growing Profit Margin: PCA became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: PCA has become profitable over the past 5 years, growing earnings by -40.1% per year.

Accelerating Growth: PCA has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: PCA has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (12.2%).

Return on Equity

High ROE: Whilst PCA's Return on Equity (122.06%) is outstanding, this metric is skewed due to their high level of debt.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/12/11 08:11
End of Day Share Price 2023/12/08 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PCAS SA is covered by 4 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Claire DerayKepler Cheuvreux
Harold De DeckerODDO BHF Corporate & Markets
Geoffroy MichaletPortzamparc BNP Paribas